Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 1096-1100

  MacGowan, Alasdair P ^a,b   Bowker, Karen E ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GEMIFLOXACIN; GENE PRODUCT; LEVOFLOXACIN; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MUTATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HALF-LIFE; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MUTATION; NAPHTHYRIDINES; OFLOXACIN; STREPTOCOCCUS PNEUMONIAE;

EID: 0037416982     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.1096-1100.2003     Document Type: Article

References (15)

1. Aeschlimann, J. R., G. W. Kaatz, and M. J. Rybak. 1999. The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in vitro model. J. Antimicrob. Chemother. 44:343-349.
2. British Society for Antimicrobial Chemotherapy Working Party. 1991. A guide to sensitivity testing. British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom.
3. Broskey, J., K. Coleman, M. N. Gwynn, L. McCloskey, C. Traini, L. Voelker, and R. Warren. 2000. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 45(Suppl. S1):95-99.
4. Broughall, J. M. 1978. Aminoglycosides, p. 194-206. In D. S. Reeves, I. Phillips, J. D. Williams, and R. Wise (ed.), Laboratory methods in antimicrobial chemotherapy. Churchill Livingstone, Edinburgh, United Kingdom.
5. King, A., J. May, G. French, and I. Phillips. 2000. Comparative in vitro activity of gemifloxacin. J. Antimicrob. Chemother. 45(Suppl. S1):1-12.
6. Lacy, M. K., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
7. Lister, P. D., and C. C. Saunders. 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 43:79-86.
8. MacGowan, A. P., K. E. Bowker, M. Wootton, and H. A. Holt. 1999. Activity of moxifloxacin, administered once a day, against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrob. Agents Chemother. 43:1560-1564.
9. MacGowan, A. P., C. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker. 2000. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin. J. Antimicrob. Chemother. 46:73-78.
10. MacGowan, A. P., C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker. 2001. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae explored using an in vitro pharmacokinetic model of infection. Antimicrob. Agents Chemother. 45:2916-2921.
11. MacGowan, A. P., C. A. Rogers, H. A. Holt, and K. E. Bowker. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 47:1088-1095.
12. Rittenhouse, S., L. McCloskey, J. Broskey, N. Niconovich, C. Jakielaszek, J. Poupard, and K. Coleman. 2000. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J. Antimicrob. Chemother. 45(Suppl. S1):23-27.
13. Woodnutt, G. 2000. Pharmacodynamics to combat resistance. J. Antimicrob. Chemother. 46:25-31.
14. Xuan, D., M. Zhong, H. Mattoes, K. Q. Bui, J. McNabb, D. P. Nicolau, R. Quintilliani, and C. H. Nightingale. 2001. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model. Antimicrob. Agents Chemother. 45:794-799.
15. Zhanel, G. G., M. Walters, N. Laing, and D. J. Hoban. 2001. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 47:435-440.